Nonprofit models support strategic boldness to develop gene therapies for rare diseases
Non-profit organisations play a crucial role in supporting rare disease therapy development and rescuing shelved programmes, where commercial interest may…
All articles by Jam Bensilum
Jam Bensilum
Jam Bensilum is a healthcare and pharmaceutical reporter. She has a background in medical communications with extensive experience across both medical affairs and publications. She holds an MSc in Molecular Medicine from Imperial College London and has interests in oncology, infectious disease, biologics, mental health and women’s health.
-
-
RNA-targeting small molecules: a new frontier of drug discovery
While small molecules have long been the cornerstone of the pharmaceutical industry, there is increasingly a demand for innovative precision…
-
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
Solid Biosciences is positioning itself for a potentially “transformative” year as it builds on its 2025 success and centres its…
-
JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries
As Regeneron faces loss of exclusivity for two of its top-performing blockbuster drugs, Eylea and Dupixent, the company will continue…
-
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
AstraZeneca has agreed to acquire Boston-based Modella AI as part of a strategy to speed up drug development across its…
-
JPM26: J&J leans on immunology launches to fuel annual growth
Johnson & Johnson (J&J) expects continued growth in 2026, bolstered by recent and new product launches within the immunology space,…
-
Enriched patient data needed to uncover sex differences in Alzheimer’s trials
Researchers say that women are twice as likely to develop Alzheimer’s disease as men. However, despite recent advances in treatments…
-
Precision medicine approaches needed in oncology to match evolving SoC
As the standard of care (SoC) for new drugs in oncology continues to improve, trials need to be designed with…
-
Investors bet on newer technology and indications for CGTs
As confidence grows for innovative in vivo strategies, some investors are saying they could be the future of the cell…
-
Redefining clinical trials in oncology and rare diseases across the Europe
Later this month, experts from the pharmaceutical and biotechnology industry and patient advocacy space will gather in Munich, Germany, to…